Orthofix's simultaneous sacking of its chief legal officer, chief financial officer and CEO 18 months ago for what the maker of orthopedic medical devices described at the time only as "offensive ...

From regulatory clearances to partnerships, here are five key developments from spine and orthopedic medtech companies since ...

Orthofix’s TrueLok Elevate transverse bone transplant system earned FDA 510(k) clearance and CE Mark from the European Union. TrueLok Elevate is designed for limb preservation and addresses bony or ...

My name is Jeannie, and I will be your conference operator today. At this time, I would like to welcome everyone to the Orthofix Q4 2024 earnings call. All lines have been placed on mute to ...

Orthofix is discontinuing its M6-C and M6-L total disc replacement devices as part of its strategic focus on spinal and deformity correction, the company said Feb. 25. Global sales for the ...

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced it has received U.S. Food and Drug Administration (FDA ...

LEWISVILLE, Texas, March 03, 2025--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that the Company will participate in the 37th ...

Orthofix, which belongs to the Zacks Medical - Instruments industry, posted revenues of $215.66 million for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 1.53%. This ...

Connor Clark & Lunn Investment Management Ltd. increased its position in shares of Orthofix Medical Inc. (NASDAQ:OFIX – Free Report) by 60.2% during the 4th quarter, according to its most recent ...

Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced the appointment of Vickie ...

Orthofix (OFIX) came out with quarterly earnings of $0.02 per share, missing the Zacks Consensus Estimate of $0.06 per share. This compares to loss of $0.10 per share a year ago. These figures are ...